uploads/2017/11/Chart-005-Oncology-1.jpg

Behind Eli Lilly’s Alimta and Other Oncology Products in 3Q17

By

Updated

Oncology franchise

Eli Lilly’s (LLY) oncology products portfolio includes the drugs Alimta, Cyramza, Erbitux, and Portrazza. In 3Q17, overall revenues from oncology products fell due to lower sales of Alimta, Erbitux, and Portrazza, partially offset by a rise in Cyramza sales.

Article continues below advertisement

Alimta

Alimta, a blockbuster chemotherapy drug, reported revenues of $514.5 million during 3Q17, representing a 10% YoY (year-over-year) fall in revenues, compared with $570 million during 3Q16. This fall was driven by a 6% decline in US sales and a 14% decline in non-US sales, marginally offset by a positive impact of foreign exchange.

Erbitux

Erbitux, an oncology drug for metastatic colorectal cancer and head and neck cancer, reported revenues of $163 million during 3Q17, representing an 11% YoY fall in revenues, compared with $185 million in 3Q16. This decline was driven by a 12% fall in US sales, an 8% fall in non-US sales, and a -2% impact of foreign exchange.

Other drugs for the treatment of metastatic colorectal cancer and head and neck cancer include Amgen’s (AMGN) Vectibix and Roche’s Avastin.

Other drugs in the oncology franchise

LLY’s oncology franchise also includes Cyramza and Portrazza. Cyramza reported revenues of $196 million during 3Q17, representing a 23% YoY rise, compared with $159 million in 3Q16. This growth was driven by a 4% rise in US sales and a 38% rise in non-US sales.

Portrazza reported revenues of ~$2.3 million during 3Q17, representing a 57% YoY fall.

Notably, the PowerShares Dynamic Pharmaceuticals ETF (PJP) has 2.8% of its total assets in Eli Lilly (LLY), 3.0% in Perrigo (PRGO), 4.2% in Merck (MRK), and 4.9% in Amgen (AMGN).

Advertisement

More From Market Realist